Oncolytics Biotech Stock Price - ONCY

1.35
-0.10 (-6.9%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncolytics Biotech Inc ONCY NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 1.45 1.3901 1.52 1.44 1.45 00:00:06
Bid Price Ask Price Spread Spread % News
1.35 1.72 0.37 21.51% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,662 592,453 $ 1.47 $ 869,664 770,265 0.351 - 6.02
Last Trade Time Type Quantity Stock Price Currency
19:36:45 formt 1,100 $ 1.35 USD

Oncolytics Biotech Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 54.19M 37.38M $ -17.04M -0.78 - 19.68M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Oncolytics Biotech News

Loading Messages....

Latest ONCY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONCY Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.451.65591.261.39317,8380.000.0%
1 Month2.622.660.921.50745,865-1.17-44.66%
3 Months4.024.160.922.511,025,122-2.57-63.93%
6 Months0.436.020.402.561,208,4291.02237.21%
1 Year1.846.020.3512.39680,847-0.39-21.2%
3 Years5.857.400.3512.47405,613-4.40-75.21%
5 Years5.857.400.3512.47405,613-4.40-75.21%

Oncolytics Biotech Description

Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotype through innate and adaptive immune responses. Our clinical development plan is based on these two components of the mechanism of action, with a focus on obtaining regulatory approval as soon as possible.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.